Uncover the latest and most impactful research in Muscarinic Receptor Modulation in Neurological Disorders. Explore pioneering discoveries, insightful ideas and new methods from leading researchers in ...

Subtle changes in neurotransmission that occur during Alzheimer’s disease have been tough to track in living people. A new positron emission tomography tracer may change that. In the January 12 ...

Muscarinic acetylcholine receptors (mAChRs) constitute a family of five G protein-coupled receptors (M1–M5) that mediate the diverse actions of acetylcholine in the central nervous system.

An international study led by Monash University has, for the first time, harnessed cutting-edge technology to reveal new and unprecedented information of how a special class of drugs, known as ...

Shanghaitech University has synthesized thiadiazole derivatives acting as muscarinic acetylcholine M4 receptor agonists reported to be useful for the treatment of schizophrenia and Alzheimer’s disease ...

Four presentations highlight significant treatment gaps in isolated dystonia and new research providing mechanistic rationale for targeting muscarinic cholinergic receptors for treating movement ...

Cocaine, opioids, and other drugs of abuse disrupt the brain's reward system, often shifting users' priorities to obtaining more drug above all else. For people battling addiction, this persistent ...

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be useful for the treatment of psychiatric ...

Long-acting muscarinic antagonists (LAMAs), as add-on therapy to inhaled corticosteroids, improved peak forced expiratory volume in 1 second (FEV1) and reduced exacerbations in children younger than ...

According to the World Health Organization (WHO), over 22% of the global population smokes, with more than 9 million smoking-related deaths reported annually. Effective treatments to alleviate ...

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neuro ...